Coherus Oncology (NASDAQ:CHRS) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Coherus Oncology (NASDAQ:CHRS) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.03), FiscalAI reports. The company had revenue of $12.75 million for the quarter, compared to analysts’ expectations of $14.09 million.

Here are the key takeaways from Coherus Oncology’s conference call:

• The company completed its strategic transformation into an innovative oncology firm, having divested its biosimilars, reduced secured/convertible debt by over 90% to $38.8 million, and strengthened the balance sheet with ~$172.1 million in cash and a recent $50 million raise.
• Commercial momentum for LOQTORZI accelerated — full‑year 2025 net revenue grew to $40.8M (113% YoY) with Q4 demand up 15.5% QoQ — and management targets a ~$175M peak annual run‑rate (≈70% market share) by 2028 to help fund operations.
• Pipeline progress includes two differentiated assets — tagmokitug (CCR8 Treg depleter) and Casdozokitug (anti‑IL‑27) — multiple trials are underway and the company expects initial clinical data readouts from mid‑2026; a strategic collaboration with J&J to test tagmo + a T‑cell engager in prostate cancer provides external validation and potential cost sharing.
• Management has materially cut SG&A and headcount (≈35% reduction) while increasing R&D spend to support the new pipeline, and says current cash plus recent financing is sufficient to fund key milestones into 2027 though further partnering may be used to offset pivotal costs.
• Scientific and execution risks remain — the CCR8 class has shown limited single‑agent activity historically and tagmokitug’s benefit appears to require combinations to activate infiltrating T cells, and clinical readout timing depends on accrual and scan schedules which could delay value‑creating catalysts.

Coherus Oncology Stock Performance

Shares of Coherus Oncology stock opened at $1.93 on Tuesday. Coherus Oncology has a 1-year low of $0.71 and a 1-year high of $2.62. The company has a current ratio of 1.24, a quick ratio of 1.23 and a debt-to-equity ratio of 0.42. The company has a 50 day moving average of $1.78 and a 200-day moving average of $1.55. The company has a market cap of $288.48 million, a PE ratio of 1.45 and a beta of 1.05.

Key Coherus Oncology News

Here are the key news stories impacting Coherus Oncology this week:

• Positive Sentiment: LOQTORZI commercial growth and balance-sheet improvement — Net revenue for LOQTORZI more than doubled to $40.8M in 2025 (from $19.1M in 2024); management also disclosed a ~90% reduction in secured and convertible debt (from $480M to ~$38.8M) and $172.1M in year-end cash, cash equivalents and marketable securities, which materially improves runway and reduces leverage. Press Release
• Positive Sentiment: Management tone on the earnings call emphasized commercial traction and the execution of its deleveraging plan, which appears to have reassured investors about future prospects and cash runway. Earnings Call Transcript
• Neutral Sentiment: Market data on short interest is inconsistent/odd (reports show zero shares short with anomalous changes), so no clear signal from short-sellers at this time. This appears to be data noise rather than a new market driver. (internal market data entry)
• Negative Sentiment: Q4 results missed expectations — Coherus reported a loss of $0.34/share versus a consensus loss of $0.31, and revenue of $12.75M missed the ~$14.09M estimate. The quarterly operating miss is a near-term headwind for sentiment. Zacks: Q4 Miss

Analyst Upgrades and Downgrades

Separately, Oppenheimer assumed coverage on Coherus Oncology in a report on Thursday, January 22nd. They issued an “outperform” rating and a $10.00 price objective for the company. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Coherus Oncology presently has a consensus rating of “Hold” and an average target price of $5.51.

Hedge Funds Weigh In On Coherus Oncology

Several institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC purchased a new stake in shares of Coherus Oncology during the fourth quarter valued at approximately $938,000. Panagora Asset Management Inc. increased its position in shares of Coherus Oncology by 17.8% in the fourth quarter. Panagora Asset Management Inc. now owns 1,620,271 shares of the biotechnology company’s stock worth $2,301,000 after purchasing an additional 244,303 shares during the last quarter. UBS Group AG raised its position in Coherus Oncology by 38.5% during the third quarter. UBS Group AG now owns 795,941 shares of the biotechnology company’s stock valued at $1,305,000 after purchasing an additional 221,410 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Coherus Oncology by 52,980.1% in the 1st quarter. Acadian Asset Management LLC now owns 196,927 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 196,556 shares in the last quarter. Finally, Bridgeway Capital Management LLC increased its position in shares of Coherus Oncology by 72.9% in the fourth quarter. Bridgeway Capital Management LLC now owns 441,000 shares of the biotechnology company’s stock valued at $626,000 after acquiring an additional 186,000 shares during the period. 72.82% of the stock is owned by institutional investors and hedge funds.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.